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Abstract
The primary role of the innate immune response is to limit the spread of infectious pathogens, with activation of Toll-like
receptor (TLR) and RIG-like receptor (RLR) pathways resulting in a pro-inflammatory response required to combat infection.
Limiting the activation of these signaling pathways is likewise essential to prevent tissue injury in the host. Triad3A is an E3
ubiquitin ligase that interacts with several components of TLR signaling and modulates TLR activity. In the present study, we
demonstrate that Triad3A negatively regulates the RIG-I RNA sensing pathway through Lys
48-linked, ubiquitin-mediated
degradation of the tumor necrosis factor receptor-associated factor 3 (TRAF3) adapter. Triad3A was induced following
dsRNA exposure or virus infection and decreased TRAF3 levels in a dose-dependent manner; moreover, Triad3A expression
blocked IRF-3 activation by Ser-396 phosphorylation and inhibited the expression of type 1 interferon and antiviral genes.
Lys
48-linked ubiquitination of TRAF3 by Triad3A increased TRAF3 turnover, whereas reduction of Triad3A expression by
stable shRNA expression correlated with an increase in TRAF3 protein expression and enhancement of the antiviral response
following VSV or Sendai virus infection. Triad3A and TRAF3 physically interacted together, and TRAF3 residues Y440 and
Q442—previously shown to be important for association with the MAVS adapter—were also critical for Triad3A. Point
mutation of the TRAF-Interacting-Motif (TIM) of Triad3A abrogated its ability to interact with TRAF3 and modulate RIG-I
signaling. TRAF3 appears to undergo sequential ubiquitin ‘‘immuno-editing’’ following virus infection that is crucial for
regulation of RIG-I-dependent signaling to the antiviral response. Thus, Triad3A represents a versatile E3 ubiquitin ligase
that negatively regulates RIG-like receptor signaling by targeting TRAF3 for degradation following RNA virus infection.
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Introduction
Upon recognition of specific molecular components of viruses,
the host cell activates multiple signaling cascades that stimulate an
innate antiviral response, resulting in the disruption of viral
replication, and the mobilization of the adaptive arm of the
immune system. Central to the host antiviral response is the
production of type 1 interferons (IFNs), a large family of
multifunctional immunoregulatory proteins. Multiple Toll like
receptor (TLR)-dependent (TLR-3, -4, -7 and 9) and RIG-I-like
receptor (RLR) pathways are involved in the cell specific
regulation of Type I IFNs, with accumulating evidence that
cooperation between different pathways is required to ensure a
robust and controlled activation of antiviral response [1,2,3]. RIG-
I-like receptors (RLRs) - the retinoic acid-inducible gene-I (RIG-I)
and melanoma differentiation-associated gene-5 (MDA-5) - are
novel cytoplasmic RNA helicases that recognize viral RNA present
within the cytoplasm. Although both TLR7 and TLR9 are critical
for recognition of viral nucleic acids in the endosomes of
plasmacytoid dendritic cells (pDCs), most other cell types
recognize viral RNA intermediates through the RLR arm of the
innate immune response [4,5,6]. Structurally, RIG-I contains two
caspase activation and recruitment domains (CARD) at its N-
terminus and RNA helicase activity in the C-terminal portion of
the molecule [4]. The C-terminal regulatory domain (CTD) (aa
792–925) of RIG-I binds viral RNA in a 59-triphosphate-
dependent manner and activates RIG-I ATPase inducing RNA-
dependent dimerization and structural alterations that enable the
CARD domain to interact with other downstream adapter
protein(s) leading to the transcription of antiviral genes [7,8,9].
RIG-I-dependent signaling to the IKKa/b complex and to
TBK1/IKKe is transmitted via a CARD domain containing
adapter molecule – alternatively named mitochondrial antiviral
signaling (MAVS), interferon-b stimulator 1 (IPS-1), virus induced
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(CARDIF) [10,11,12,13]. MAVS localizes to the outer mitochon-
dria membrane via a C-terminal mitochondrial transmembrane
targeting domain (TM), and its mitochondrial localization acts as a
pivotal point for triggering the antiviral cascade via activation of
NF-kB and IRF-3 [3,14,15,16].
Activation of TLRs and RLRs results in the dissemination of an
antiviral and antimicrobial cascade necessary to combat invading
pathogens [17,18,19]. Limiting the intensity and duration of TLR
and RLR signaling is likewise essential to prevent this protective
response from causing inflammatory or autoimmune injury to the
host. Ubiquitination is a post-translational modification by which
signaling is suppressed in many regulatory pathways [20]. Lys
48-
linked ubiquitination is one of the most common pathways to
target proteins for 26S proteasomal degradation [21], whereas
Lys
63-linked ubiquitination is involved in protein-protein interac-
tions, recruitment, and assembly of signaling complexes [22,23]. It
has become clear that ubiquitination of signaling adapters is an
integral part of NF-kB and IFN signaling in response to virus
pathogen associated molecular patterns (PAMPs). Deubiquitinat-
ing enzymes that remove Lys
63-linked ubiquitin are also emerging
as key negative regulators of the IFN and NF-kB pathways
[16,24,25,26,27]. For example, the deubiquitinating enzyme A
(DUBA), a novel OTU-domain DUB negatively regulates IFN
signaling following RIG-I, MDA5 or TLR3 stimulation [28].
DUBA specifically removes Lys
63-linked ubiquitin chains from
TRAF3, resulting in the disruption of interaction between TRAF3
and the downstream kinases IKKe and TBK1 and subsequent
blockade of IRF-3 and IRF-7 phosphorylation [28].
The activation of RIG-I/MDA-5 ultimately leads to the TM-
dependent dimerization of the MAVS N-terminal CARD
domains, thereby providing an interface for direct binding to
and activation of the tumor necrosis factor (TNF) receptor-
associated factor (TRAF) family members that are involved in both
the IFN and NF-kB arms of the innate immune response [29,30].
TRAF3 is an adapter molecule that is required for the induction of
type I IFN and anti-inflammatory cytokine interleukin-10 (IL-10),
but is dispensable for expression of pro-inflammatory cytokines in
response to viral infection and TLR ligation in bone marrow-
derived macrophages (BMMs), plasmacytoid dendritic cells
(pDCs), and murine embryonic fibroblasts (MEFs) [31,32].
TRAF3 was the first TRAF demonstrated to directly associate
with CD40. Subsequently, it was shown that TRAF3 negatively
regulates CD40 signaling by competing with TRAF2 for CD40
binding, thus impeding CD40-TRAF2 mediated JNK and NF-kB
activation [33]. Crystal structure of the binding crevice of TRAF3
bound in complex with a 24-residue fragment of the cytoplasmic
portion of BAFF receptor (BAFF-R), revealed two amino acids in
TRAF3 -Y440A and Q442- that are involved in BAFF-R
interaction [34]. Interestingly, other TNFRs such as CD40
contain similar TRAF-interacting motifs (TIMs), defined by the
consensus sequence PxQx(T/S), that interact with the same
binding crevice on TRAF3 [35,36]. In addition, the TRAF family
member–associated NF-kB activator (TANK) adapter and the
viral oncogene LMP1 of the Epstein Barr Virus also bind to the
same structural crevice of TRAF3 [37,38]. MAVS regulation of
type I IFN induction is achieved by direct and specific interaction
with the TIM of TRAF3; interestingly point-mutation of the TIM
domain completely abrogates TRAF3-mediated IFN-a production
in response to Sendai virus infection [39].
Triad3A is a RING finger type E3 ubiquitin-protein ligase that
promotes Lys
48-linked ubiquitination and proteolytic degradation
of TLR4 and TLR9 and negatively regulates their activation by
lipopolysaccharide and CpG-DNA, respectively [40]. Triad3A is
the most abundant alternatively spliced form of the Triad family.
In addition, Triad3A interacts and promotes down-regulation of
two TIR domain containing adapter molecules, TIR-domain-
containing adapter-inducing IFN-b (TRIF) and TRIF-related
adapter molecule (TIRAP). Moreover, Triad3A acts as a negative
regulator of TNF-a signaling by interacting with the TIR
homologous (TIRH) domain containing protein receptor-interact-
ing protein 1 (RIP1) [41]. This interaction effectively disrupts
RIP1 binding to the TNF-R1 complex and impedes RIP-1-
mediated NF-kB activation [41].
The identification of a TIM sequence in the N-terminus of
Triad3A -using a program written in python language (http://
www.biopython.org)- as well as the previously characterized
function of Triad3A in TLR signaling, prompted us to investigate
the role of Triad3A in the regulation of the RIG-I/MAVS
signaling via TRAF3. In the present study, we demonstrate that
Triad3A negatively regulates the RIG-I signaling pathway through
Lys
48-linked ubiquitin-mediated degradation of TRAF3, resulting
in the inhibition of the type I IFN response.
Results
Triad3A disrupts RIG-I signaling
The identification of a TIM domain in Triad3A prompted us to
examine the ability of Triad3A to inhibit RIG-I mediated
activation of IFNB gene transcription; a constitutively active form
of RIG-I (aa 1-229, DRIG-I), the MAVS adapter or IKKe, were
co-expressed together with Triad3A in 293T cells, together with
an IFNB promoter luciferase reporter. A low basal activity of the
IFNB promoter was not affected by Triad3A expression
(Figure 1A), while co-expression of DRIG-I, MAVS, or IKKe
resulted in 196, 132, 61-fold stimulation of the IFNB promoter,
respectively (Figure 1A). Co-expression of Triad3A with DRIG-I
or MAVS resulted in a complete inhibition of IFNB promoter
activity, whereas IKKe mediated activation of the IFNB promoter
remained unchanged (Figure 1A). Similar results were also
obtained with the NF-kB response (Figure 1B); expression of
DRIG-I, MAVS or IKKe, (co-expressed together with IRF-7)
activated IFNA4 promoter activity 34, 18, 49-fold, respectively,
while co-expression of Triad3A blocked IFNA4 activation
(Figure 1C). Furthermore, Triad3A blocked interferon stimulated
Author Summary
RNA virus infection is detected through TLR-dependent
and TLR-independent mechanisms. Early viral replicative
intermediates are detected by two recently characterized
cystolic viral RNA receptors, RIG-I and MDA-5, leading to
the production of pro-inflammatory cytokines and type I
interferons (IFNs). Dysfunctional responses, either failure to
respond or hyper-responsiveness, may lead to both acute
and chronic immunodeficiency and inflammatory diseases.
Thus, the intensity and duration of RLR signaling must be
tightly controlled. One general mechanism by which
innate immune receptors and their downstream adapters
are regulated involves protein degradation mediated by
the ubiquitination pathway. Our study demonstrates that
the E3 ubiquitin ligase Triad3A negatively regulates the
RIG-I-like receptor pathway by targeting the adapter
molecule TRAF3 for proteasomal degradation through
Lys
48-linked ubiquitin-mediated degradation. Thus,
Triad3A represents a key molecule involved in the negative
regulation of the host antiviral response triggered by RNA
virus infection.
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(Figure 1D). A dose-response curve was performed using the ISRE
promoter with increasing amounts of Triad3A and DRIG-I,
MAVS, TRIF, or TBK1 expression plasmids; DRIG-I resulted in
893-fold induction of the ISRE promoter, and Triad3A co-
expression diminished activation in a dose dependent manner
(Figure S1A). Similarly, MAVS or TRIF adapters activated the
ISRE by 785- and 863-fold, respectively; Triad3A again
dramatically reduced ISRE activation (Figure S1B, S1C). In
contrast, Triad3A did not significantly decrease TBK1-mediated
ISRE activation (Figure S1D). Triad3A co-expression with MDA5
or an active form of TLR3 fused to CD4 (CD4-TLR3) resulted in
a complete inhibition of IFNB promoter activity (Figure S2A).
Triad3A inhibited MDA5-induced NF-kB promoter activity;
however Triad3A inhibition of CD4-TLR3 mediated NF-kB
promoter activity was less pronounced (Figure S2B). These
experiments suggested that Triad3A was a strong inhibitor of
RIG-I signaling to IRF-3, IRF-7 and NF-kB and suggested that
Triad3A may target an adapter molecule common to both the
TLR and RLR signaling pathways.
Triad3A inhibits downstream IFN activation
As a measure of activation of the IFN signaling pathway, the
phosphorylation state of IRF-3 was evaluated by immunoblot in
the presence of Triad3A using the phosphospecific Ser-396 IRF-3
antibody [42]. DRIG-I co-expression induced Ser-396 IRF-3
phosphorylation (Figure 2, lane 3), while co-expression of Triad3A
completely blocked IRF-3 phosphorylation (Figure 2, lane 4).
MAVS expression likewise induced Ser-396 IRF-3 phosphoryla-
tion (Figure 2, lanes 3–5); that was abrogated by Triad3A (Figure 2,
lanes 4–6). In contrast, TBK1 co-expression in the presence or
absence of Triad3A did not alter the IRF-3 phosphorylation state
(Figure 2, lanes 7–8). Complementing the phosphorylation status,
Triad3A also inhibited DRIG-I and MAVS-induced dimerization
of endogenous IRF-3 (Figure 2, lanes 4–6), but did not affect
TBK1-induced IRF-3 dimer formation (Figure 2, lanes 7–8),
indicating that Triad3A targets RLR signaling upstream of TBK1.
Triad3A is induced by RNA virus infection and regulates
TRAF3 levels
Previous studies demonstrated that the E3 ligase RNF1252a
negative regulator of RIG-I2 was induced following IFN-a and
poly(I:C) treatment [43]. Endogenous Triad3A protein was
induced in human bronchial epithelial A549 cells following
dsRNA treatment for 6h, vesicular stomatitis virus (VSV), or
Sendai virus (SeV) infection for 16h; correlating with the
degradation of TRAF3 protein (Figure 3A). Moreover, Triad3A
Figure 1. Triad3A inhibits RIG-I/MAVS-mediated transactiva-
tion of type 1 IFN promoters. 293T cells were transfected with
pRLTK control plasmid and (A) IFNB-pGL3, (B), NF-kB, (C) IFNA4-pGL3
reporter plasmids, the pcDNA3 vector or expression plasmids encoding
DRIG-I, MAVS, IKKe, as well as Triad3A expression plasmid as indicated.
In addition,100 ng of IRF-7 plasmid was added per well for the
transactivation of the IFNA4 promoter. (D) 293T cells were transfected
with pcDNA3 or Triad3A expression vector, along with pRLTK control
plasmid (100 ng) and ISRE-Luc reporter plasmid (200 ng). 24h post-
transfection cells were infected with Sendai virus for 16h. Luciferase
activity was analyzed at 24h post-transfection by the Dual-Luciferase
Reporter assay as described by the manufacturer (Promega). Relative
luciferase activity was measured as fold activation (relative to the basal
level of reporter gene in the presence of pcDNA3 vector after
normalization with co-transfected RLU activity); values are mean 6
S.D. for three experiments.
doi:10.1371/journal.ppat.1000650.g001
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not shown). In addition, it was determined by time-course analysis
that 6h dsRNA treatment and 16h virus infection resulted in
maximal TRAF3 degradation (Figure S3). Expression of increas-
ing amounts of Triad3A decreased TRAF3 levels in a dose-
dependent manner (Figure 3B). Additionally, SeV-mediated
degradation of TRAF3 in A549 cells was blocked by the
proteasome inhibitors lactacystin and Mg132, but not by the
lysosomal protease inhibitor E64 (Figure 3C).
Stable knock-down of Triad3A correlates with increased
TRAF3 protein levels and ISG expression following virus
infection
To further confirm the involvement of Triad3A in regulating
TRAF3 turnover, two shRNA expression vectors - shRNA1 and
shRNA2 that target Triad3A nucleotide sequences 1,532–1,551
and 1,195–1,214, respectively – were used to stably knock-down
Triad3A in A549 cells. Knock-down of Triad3A resulted in a 5-
fold increase in TRAF3 protein levels (Figure 4A). Interference
with endogenous Triad3A also modulated the ISRE promoter;
ISRE activity was 3-fold higher in Triad3A knock-down cells
infected with SeV, compared to cells expressing scrambled shRNA
(Figure 4B). [43]. To investigate the physiological effects of
Triad3A inhibition on downstream IFN-stimulated target genes,
expression of multiple ISGs were examined by quantitative PCR
in A549-Triad3A knock-down cells. SeV infection (40 hemagglu-
tination units/ml (HAU)) in Triad3A knockdown cells were led to
a 3–4 fold increase in IFN-b and IFN-a2 mRNA expression 12h
post-infection (p.i.) compared to control cells (Figure 4C).
Similarly, IP-10 ISG56, IS15 transcripts were increased 3–4 fold
at 12h p.i. (Figure 4C), while STAT1 levels remained relatively
constant (Figure 4C). In addition, levels of IFN-a and IFN-b
released in the supernatant monitored by ELISA increased 2-fold
following SeV infection (Figure 4D). Finally, in VSV infected
A549 cells, VSV proteins (nucleocapsid (N), surface glycoprotein
(G), and matrix (M)) were detected at 8h p.i., whereas in Triad3A
knock-down cells, VSV protein expression was delayed, with viral
proteins detected only at 16h post-infection (Figure 4E). Notably,
in A549 control cells TRAF3 protein levels decreased over time
following virus infection, whereas in Triad3A knock-down cells
TRAF3 protein levels remained constant (Figure 4E). These results
indicate the involvement of Triad3A in regulating IFN and NF-kB
dependent gene expression following RNA virus infection.
TIM domain of Triad3A interacts with the TRAF domain of
TRAF3
The functional specificity of TRAFs is dictated by their ability to
recognize and bind distinct structural motifs, termed the TRAF-
interacting motif (TIM), with the consensus sequence PxQx(T/S).
This motif contacts TRAF proteins within a structurally conserved
binding crevice within the C-terminal TRAF domain (Figure 5A).
Using multiple sequence alignment, we identified an N-terminal
motif in Triad3A - amino acid residues 316 -PMQES- 320 - with
substantial homology to the consensus TIM that is also found on
the adapter molecule MAVS – amino acid residues 143-PVQDT-
147 (Figure 5A). Previously, it has been reported that the TIM
domain of MAVS interacts with amino acid residues Y440 and
Q442 within the TRAF domain of TRAF3. As a result, co-
Figure 2. Triad3A inhibits DRIG-I and MAVS-mediated activation of IRF-3. 293T cells were cotransfected with 500 ng of IRF-3, 1 mg myc-
DRIG-I, myc-MAVS, or GFP-TBK1 and 2 mg of Flag-Triad3A expression construct as indicated. Whole cell extracts (40 mg) were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by immunoblotting for IRF-3 pSer396, Flag-Triad3A, myc-DRIG-I, myc-MAVS, GFP-
TBK1, and b-Actin. For IRF-3 dimerization assay, 293T cells were transfected with 1 mg of pcDNA3-, DRIG-I-, MAVS-, or TBK1-expressing plasmid
together with 2 mg of pcDNA3 or Triad3A-expressing plasmid as indicated above the lanes. Whole cell extracts (40 mg) were subjected to SDS-PAGE
or native PAGE and probed with anti-IRF-3 Ser-396 phosphospecific antibody to detect IRF-3 phosphorylation or anti-IRF-3 antibody to detect IRF-3
dimerization.
doi:10.1371/journal.ppat.1000650.g002
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PLoS Pathogens | www.plospathogens.org 4 November 2009 | Volume 5 | Issue 11 | e1000650Figure 3. Triad3A is induced by RNA virus infection and regulates TRAF3 levels. (A) A549 cells were treated with 20 mg/ml dsRNA for 6h, or
infected with VSV at a MOI 1 or infected with Sendai Virus for 16h. Whole cell extract (40 mg) was resolved by SDS-7.5% PAGE and transferred to
nitrocellulose and probed with anti-Triad3A, anti-TRAF3, anti-ISG56, anti-RIG-I and anti-b-Actin antibodies. (B) 293T cells were co-transfected with
expression vectors for myc-tagged TRAF3 and increasing amount of expression vector for Flag-tagged Triad3A as indicated. The cells were
subsequently lysed, and cell lysates were resolved by SDS-PAGE. The expression levels of TRAF3, Triad3A, and b-Actin were analyzed by
immunoblotting with antibodies against myc, Flag, or b-Actin, respectively. (C) A549 cells were infected with Sendai virus 40 HAU/ml and treated with
either 5mM of lactacystin or 10mM of Mg132 or 5mM of E64. Whole cell extracts were resolved by SDS-7.5% PAGE and transferred to nitrocellulose and
probed with anti-TRAF3, and anti-b-Actin antibodies.
doi:10.1371/journal.ppat.1000650.g003
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association of Triad3A and TRAF3; following immunoprecipita-
tion of Flag-tagged TRAF3, immunoblot analysis revealed that
TRAF3 and Triad3A co-precipitate together (Figure 5B, lane 4).
Co-immunoprecipitation of TRAF3 (Y440A/Q442A) and
Triad3A revealed that this interaction was impaired, demonstrat-
ing that the hydrophobic residues in the TRAF3 binding crevice
are important for binding to Triad3A (Figure 5B, lane 5). In the
reciprocal experiment, Triad3A S320D was unable to bind
TRAF3 in co-immunoprecipitation experiments (Figure 5C, lane
Figure 4. Stable knock-down of Triad3A increases TRAF3 protein levels and ISG expression following virus infection. (A) Whole cell
extracts from A549 stable shRNA Triad3A and shRNA control cells was resolved by SDS-7.5% PAGE, transferred to nitrocellulose and probed with anti-
Triad3A, anti-TRAF3, and anti-b-Actin antibodies. (B) Stable shRNA Triad3A and control A549 cells were transfected with pRLTK control plasmid
(100 ng) and ISRE-Luc reporter plasmid (200 ng). Approximately 24h after transfection cells were infected with Sendai virus for 16h as indicated.
Luciferase activity was analyzed by the Dual-Luciferase Reporter assay as described by the manufacturer (Promega). Relative luciferase activity was
measured as fold activation (relative to the basal level of reporter gene in the presence of pcDNA3 vector after normalization with co-transfected RLU
activity); values are mean 6 S.D. for three experiments. (C) A549 stable shRNA Triad3A and shRNA control cells were infected with Sendai virus at 40
HAU/ml from 0 to 12h p.i. DNase-treated total RNA were prepared at the indicated times and subjected to real-time PCR analysis for quantification of
IFNB, IFNA, CXCL10, ISG56, ISG15, and STAT1. Results are presented as a relative quantification based on the relative expression levels of target gene
mRNA versus B-Actin mRNA, as a reference gene (values of ratios are indicated on the bar graphs). Normalization using GAPDH mRNA levels as
reference gave similar results (data not shown). (D) Supernatants from A549 stable shRNA Triad3A and shRNA control cells infected with Sendai virus
at 40 HAU/ml were collected 14h post-infection and ELISA assay was performed for IFN-b and IFN-a. (E) A549 stable shRNA Triad3A and shRNA
control cells were infected with VSV at a MOI 1 from 0 to 16h p.i. Whole cell extract (40 mg) was resolved by SDS-7.5% PAGE and transferred to
nitrocellulose and probed with anti-VSV and anti-TRAF3.
doi:10.1371/journal.ppat.1000650.g004
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PLoS Pathogens | www.plospathogens.org 6 November 2009 | Volume 5 | Issue 11 | e1000650Figure 5. The TIM domain of Triad3A interacts with the TRAF domain. (A) Schematic representation of TRAF3, Triad3A, and MAVS. TRAF3
contains a N-terminus RING domain and a C-terminus TRAF domain where a hydrophobic binding cleft (Y440/Q442) is located. Triad3A contains a
TRIAD domain consisting of two RING domains and an ‘in-between-RING’ (IBR) domain. The N-terminus of Triad3A contains a motif (316 -PMQES-320)
that matches the consensus TRAF-intercating-motif (TIM), PxQx(T/S). MAVS adapter is composed of a N-terminus CARD domain, as well as a TIM (143-
PVQDT-147) located in the proline-rich region. In addition, the C-terminus of MAVS is composed of a Transmembrane (TM) domain for anchoring to
the outer-mitochondrial membrane. (B) 293T cells were transfected with myc-tagged Triad3A with Flag-tagged TRAF3 or Flag-TRAF3 Y440A/Q442A as
indicated, in the presence of 5mM of Lactacystin at 6h post-transfection. Whole cell extracts were immunoprecipitated with anti-Flag Ab, and then
analyzed with anti-myc Ab. (C) 293T cells were transfected with myc-tagged TRAF3 with Flag-tagged Triad3A or Flag-Triad3A S320D as indicated, in
the presence of 5mM of Lactacystin at 6h post-transfection. Whole cell extracts were immunoprecipitated with an anti-myc Ab, and then analyzed by
with anti-Flag Ab. Cell lysates were analyzed by immunoblotting with anti-myc and anti-Flag antibodies. (D,E) 293T cells were transfected with pRLTK
control plasmid, IFNB-pGL3 (D), NF-kB (E) reporter plasmid and the pcDNA3 vector or expression plasmids encoding DRIG-I, TRIF as well as Triad3A or
Triad3A S320D expression plasmid as indicated. Luciferase activity was analyzed at 24h post-transfection by the Dual-Luciferase Reporter assay as
described by the manufacturer (Promega). Relative luciferase activity was measured as fold activation (relative to the basal level of reporter gene in
the presence of pcDNA3 vector after normalization with co-transfected RLU activity); values are mean 6 S.D. for three experiments.
doi:10.1371/journal.ppat.1000650.g005
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TRAF3 degradation (Figure S4). Furthermore, Triad3A S320D
no longer inhibited DRIG-I-mediated activation of the NF-kB and
IFNb gene transcription but readily inhibited TRIF-mediated
activation (Figure 5D,E), thus indicating the specificity of the TIM
domain of Triad3A for TRAF3.
Triad3A mediates Lys 48-linked ubiquitination of TRAF3
To test whether Triad3A-mediated degradation of TRAF3 was
promoted by Lys
48-linked ubiquitination, an in vivo ubiquitination
assay was performed with Flag-tagged TRAF3, HA-tagged wild
type or (Lys
48 and Lys
63) Ub products (Figure 6A), and sub-
optimal levels of myc-tagged Triad3A and Triad3A S320D to limit
TRAF3 degradation. Following immunoprecipitation of Flag-
tagged TRAF3, immunoblot analysis revealed that Triad3A
mediated TRAF3 polyubiquitination (Figure 6B, lane 8), with
polyubiquitination increasing in the presence of Triad3A and
Mg132 (Figure 6B, lane 10), compared to TRAF3 and ubiquitin
alone (Figure 6B, lane 7). In contrast, Triad3A S320D did not
polyubiquitinate TRAF3 (Figure 6B, lane 9); furthermore, Triad3A
promoted Lys
48-linked polyubiquitination of TRAF3 (Figure 6B,
lane 13) but not Lys
63-linked polyubiquitination (Figure 6B, lane
14). Cells expressing optimal levels of Triad3A readily degraded
TRAF3 (Figure 6C, lane 2), whereas Triad3A was unable to
degrade TRAF3 in the presence of K48R and KO Ub mutants
(Figure 6C, lane 3,5).
TRAF3 undergoes biphasic polyubiquitination and
dissociates from MAVS following virus infection
As both MAVS and Triad3A contain well-characterized TIM
domains, the interaction between endogenous TRAF3 and
Triad3A was next examined in SeV-infected A549 cells. Following
co-immunoprecipitation with anti-TRAF3 antibody, a MAVS-
TRAF3 complex was detected at 8h p.i., whereas at 16h, Triad3A
disrupted this interaction by associating directly with TRAF3,
suggesting that both Triad3A and MAVS compete for the same
binding residues on TRAF3 (Figure 7A). Importantly, a kinetic
analysis of in vivo TRAF3 ubiquitination demonstrated that
endogenous TRAF3 was subject to differential biphasic poly-
ubiquitination; using Lys
48 and Lys
63 specific Ub antibodies [44],
early Lys
63-linked polyubiquitination was detected at 4h and 8h
p.i. (Figure 7B), whereas a late phase Lys
48-linked polyubiquitina-
tion of TRAF3 was detected at 12h and 16h p.i. (Figure 7B). Thus,
TRAF3- mediated antiviral signaling appears to be regulated by
recruitment of TRAF3 to the MAVS TIM, followed by Triad3A
competition for the same binding crevice of TRAF3 (Figure 8).
Discussion
The present study demonstrates that the E3 ubiquitin ligase
Triad3A blocks RIG-I-mediated signaling to NF-kB and IRF
pathways by targeting the TRAF3 adapter for degradation via
Lys
48-linked ubiquitinination. Several observations support this
conclusion: 1) co-expression of Triad3A blocked DRIG-I depen-
dent IRF-3 phosphorylation and dimerization; 2) Triad3A
expression decreased TRAF3 protein levels in a dose-dependent
manner; 3) knock-down of Triad3A by shRNA increased
endogenous TRAF3 protein levels, increased ISG mRNA levels
following virus infection, and inhibited VSV replication; 4) Lys
48-
linked ubiquitination of TRAF3 by Triad3A increased TRAF3
turnover; and 5) Triad3A and TRAF3 physically interacted
together, an interaction that was impaired by mutation of TRAF3
(Y440A/Q442A), or reciprocally by point mutation of the TIM
domain in Triad3A (S320D). TRAF3 appears to undergo a
biphasic ubiquitination following virus infection that is crucial for
regulation of RIG-I dependent signaling to the antiviral response.
Early Lys
63-linked polyubiquitination of TRAF3 leads to the
recruitment of TBK1/IKKe and subsequent activation of the
antiviral response [28], while late phase Lys
48-linked polyubiqui-
tination by Triad3A ultimately degrades TRAF3 and leads to
shut-down of the antiviral response (Figure 8).
Recent studies have highlighted the importance of ubiquitina-
tion in modulating the innate immune response to invading
pathogens via both the TLR and RLR pathways. For example, the
RIG-I cytoplasmic RNA sensor undergoes both Lys
48-linked and
Lys
63-linked ubiquitination [43,45]: the second CARD domain
undergoes TRIM25a-mediated, Lys
63-linked ubiquitination at
Lys-172, resulting in RIG-I/MAVS association and triggering of
the antiviral response [45]; RIG-I also undergoes Lys
48-linked
ubiquitination, leading to RIG-I proteasomal degradation by
RNF125 [43]. Additionally, RNF125 conjugates ubiquitin to
MDA5 and MAVS, thus inhibiting the assembly of the
downstream antiviral signaling complex [43]. Overall, multiple
steps in the RLR pathway are regulated by ubiquitination to
ensure a properly modulated antiviral cascade.
In addition to the newly described role of Triad3A in the
regulation of the RIG-I response, previous studies demonstrated
that Triad3A negatively regulates both the TLR and TNF-a
pathways by promoting Lys
48-linked, ubiquitin-mediated degra-
dation of TLR4, TLR9 and TIR domain-containing adapters
TRIF and TRAM [40,41]. Triad3A regulation of the TNF-a
pathway is achieved via a proteolysis-independent mechanism that
impedes RIP1 binding to the TNF-R1 [40,41]. Furthermore,
Triad3A promotes ubiquitination and proteasomal degradation of
RIP1 following disruption of the RIP-1-Hsp90 complex. Both
Hsp90 and Triad3A form a complex that co-ordinates the
homeostasis of RIP1; treatment of cells with geldanamycin to
disrupt the Hsp90 complex leads to proteasomal degradation of
RIP1 by Triad3A [40]. The present study further illustrates the
versatility of Triad3A as a negative regulator of innate signaling
pathways.
Both TLR and RLR pathways converge upon TRAF3 in the
activation of the antiviral cascade. TRAF3 was originally
described as a cytoplasmic adapter that interacted with CD40
and LMP1 and modulated the adaptive immune response [46,47].
The generation of TRAF3 2/2 bone marrow-derived macro-
phages established TRAF3 as a key molecule in signaling to the
production of type I IFNs that functioned as a bridge between
MAVS and the downstream kinases TBK1/IKKe [32,39].
Triad3A mediated degradation of TRAF3 results not only in the
inhibition of RIG-I signaling, but also inhibition of MDA5 and
TLR3 signaling (Figure S2A, B).
The TIM sequence of MAVS (aa 143-PVQDT-147) binds to
the hydrophobic C-terminal crevice of TRAF3 (TRAF domain)
located between amino acids Y440 and Q442 [39]. The TIM
motif represents a binding interface that recognizes different
TRAFs with varying degrees of specificity. The binding cleft in
TRAF3 has structurally adaptive ‘‘hot spots’’ that can recognize
motifs that are divergent from the consensus TIM [36].
Interestingly, Triad3A interaction with TRAF3 was impaired by
mutation of residues within the binding crevice (Y440A/Q442A)
(Figure 6B). Furthermore, Triad3A disrupts the interaction
between MAVS and TRAF3 (Figure 7A), thus highlighting the
importance of the TIM domain of Triad3A in regulating TRAF3
interactions by competitive binding.
In contrast to its positive role in the production of type I IFN,
TRAF3 negatively regulates noncanonical p100/p52 NF-kB
activation through degradation of the NF-kB inducing kinase
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48-linked polyubiquitination of TRAF3. (A) Schematic illustration of HA- wild type and ubiquitin mutants. (B)
293T cells were transfected with expression vectors for Flag-tagged TRAF3, myc-tagged Triad3A, myc-tagged Triad3AS320D, and wild type or HA-
tagged ubiquitin mutants and were treated with 10 mM of Mg132 at 6h post-transfection where indicated. Cell lysates were immunoprecipitated with
anti-Flag, and immunoblotted with anti-HA. (C) 293T cells were transfected with Flag-tagged Triad3A, myc-tagged TRAF3, and HA-tagged ubiquitin
mutants as indicated.
doi:10.1371/journal.ppat.1000650.g006
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decreased IFNB, IFNA4, and NF-kB promoter activity by targeting
TRAF3 for degradation. Although it was expected that Triad3A
driven TRAF3 degradation would enhance NF-kB promoter
activity, the observed decrease in NF-kB activity suggests that
Triad3A may disrupt other TRAF family members such as
TRAF2 and TRAF6, prevent their association with MAVS, and
thus disrupt NF-kB activation. However, it has been previously
demonstrated that Triad3A does not target TRAF2 or TRAF6 for
proteasomal degradation [41]. It is also possible that some
components of the p100/p52 pathway may be engaged down-
stream of RIG-I; this idea is strengthened by the recent report that
TNFR1-associated death domain protein (TRADD) is essential for
RIG-I/MAVS signaling, forms a complex with TRAF3/TANK/
FADD/RIP1, and leads to activation of IRF-3 and NF-kB [50].
Furthermore, the effect of Triad3A on NF-kB activation was
shown to be independent of RIP1 proteolytic degradation [41],
thus strengthening the possibility that another TRAF family
member associates with the TIM domain of Triad3A.
Previous studies demonstrated that TRAF3 signaling was tightly
regulated by the de-ubiquitinase A (DUBA) which removed Lys
63
linked Ub residues from TRAF3 and disrupted recruitment of
TBK1/IKKe and downstream IFN activation [28]. Dual
regulation of TRAF3 by DUBA and Triad3A represents a pivotal
point in the control of RLR signaling. The present results suggest a
biphasic regulation or ‘‘immune-editing’’, whereby TRAF3 is
Lys
63 polyubiquitinated early after virus infection to bridge
protein-protein interactions between MAVS and TBK1/IKKe.
Later, Lys
63 polyubiquitin is removed by DUBA to disrupt
TRAF3-TBK1/IKKe interactions [28]; TRAF3 then undergoes a
late phase Lys
48-linked polyubiquitination by Triad3A, leading to
proteasomal degradation (Figure 8). Such a multi-level regulation
of TRAF3 underscores its key role in modulating positive and
negative antiviral signaling. Furthermore, the complementary
functions of DUBA and Triad3A with respect to inhibition of
TRAF3 activity and turnover may be subject to stimuli- and tissue-
specific regulation, a topic that warrants further investigation. In
conclusion, Triad3A acts as a multi-targeting E3 ubiquitin ligase
that negatively regulates the TLR, TNF-a and RLR pathways; in
the RLR pathway, Triad3A targets TRAF3 for Lys
48-linked
polyubiquitination, leading to proteasome-dependent degradation,
as part of the host-specific mechanism that limits the antiviral
response.
Materials and Methods
Plasmid constructions and mutagenesis
Plasmids encoding DRIG-I, MAVS, IKKe,T B K 1 ,NF-kB/
pGL3, IFNB/pGL3, IFNA4/pGL3, ISRE-luc reporter, and
pRLTK were described previously [14,24,51,52]. HA-ubiquitin
and other HA-Ubiquitin constructs (HA-Ub-K48, HA-Ub-K63,
HA-Ub-K48R, HA-Ub-K63R, and HA-Ub-KO) were kind gifts
from Dr. Zhijian Chen (Department of Molecular Biology,
University of Texas Southwestern Medical Center, Dallas Texas).
MDA5 and CD4-TLR3 were kind gifts from Dr. Stephen
Goodbourn (Division of Basic Medical Sciences, St George’s,
University of London, England) and Dr. Luke A. J. O’Neill
(School of Biochemistry and Immunology, Trinity College,
Dublin, Ireland) respectively. Human Triad3A cDNA was
amplified from pKR5 Flag-Triad3A expression plasmid and
cloned into Flag and myc pcDNA3.1/Zeo. The Triad3A point
mutant S320D was introduced by Quickchange Kit according to
the manufacturer’s instructions (Stratagene). DNA sequencing
was performed to confirm the mutation. Triad3A shRNA1
Figure 7. TRAF3 undergoes biphasic polyubiquitination and dissociates from MAVS following virus infection. (A) A549 cells were
infected with Sendai virus 40 HAU/ml in the presence of 5mM of Lactacystin, immunoprecipitated with an anti-TRAF3 antibody and then analyzed by
immunoblotting with anti-Triad3A and anti-MAVS Ab. (B) A549 cells were infected with Sendai virus 40 HAU/ml in the presence of 5mM of Lactacystin
and samples were collected every 4h p.i. Cell lysates were immunoprecipitated with ant-TRAF3, and immunoblotted with Lys
48 and Lys
63 anti-
ubiquitin specific antibodies.
doi:10.1371/journal.ppat.1000650.g007
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GAGTTCTATGAGCA-39, shRNA2 targeting nucleotide se-
quence (1,195–1,214) 59-GGACACTATGCAATCACCCG-39
and shRNA control have been previously described [40]. Human
TRAF3 cDNA was amplified from pKR5 Flag-TRAF3 and
pKR5 Flag-TRAF3 Y440A/Q442A expression plasmids provid-
ed by Dr. Genhong Cheng (UCLA, USA) and were cloned into
Flag pcDNA3.1/Zeo. Mg132, lactacystin and E64 were pur-
chased from Calbiochem. dsRNA was purchased from Invivogen.
A549 cells were infected with Sendai virus (40 HAU/ml) for 16h
and were treated with either Mg132 (10mM), lactacystin (5mM) or
E64 (5mM) 6h p.i.
Cell culture, transfections, and luciferase assays
Transfections for Luciferase assay were carried out in 293T cells
grown in Dulbecco’s modified Eagle’s medium (Invitrogen)
supplemented with 10% fetal bovine serum and antibiotics.
Subconfluent 293T cells were transfected with 100 ng of pRLTK
reporter (Renilla luciferase for internal control), 200 ng of pGL-3
reporter (firefly luciferase, experimental reporter), 200 ng of
DRIG-I, MDA5, CD4-TLR3, MAVS, TRIF, IKKe, or TBK1
expression plasmids, 200 ng of pcDNA3 or Flag Triad3A/Flag
Triad3A S320D pcDNA3, and 100ng of IRF-7 plasmid as
indicated by calcium phosphate co-precipitation method. The
reporter plasmids were: IFNB pGL3, ISRE-luc, NF-kB pGL3, and
Figure 8. Model of TRAF3 dependent regulation of RIG-I signaling via sequential ubiquitination. At early times after RNA virus infection
(4–8h), MAVS interacts with TRAF3 via its TRAF interacting motif (TIM); TRAF3 is subject to Lys
63 polyubiquitination, leading to recruitment of the
downstream kinases TBK1/IKKe and production of type I IFN. Subsequently, DUBA removes Lys
63 polyubiquitination from TRAF3 which dissociates
the TRAF3-TBK1 signaling complex. At late times after infection (12–16h), Triad3A physically associates TRAF3 via its TIM which promotes Lys
48
polyubiquitination of TRAF3, and subsequent proteasomal degradation.
doi:10.1371/journal.ppat.1000650.g008
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previously described [53]. At 24h after transfection, the reporter
gene activities were measured by Dual-Luciferase Reporter Assay,
according to manufacturer’s instructions (Promega). Where
indicated, cells were treated with Sendai virus (40 HAU/ml) for
the indicated time or 16h for luciferase assays. Human A549 cells
were cultured in F12K medium (Wisent Inc.) supplemented with
10% fetal bovine serum, glutamine and antibiotics. A549 cells
were transfected either with dsRNA (20mg/ml) for 6h or infected
with VSV-AV1 (multiplicity of infection of 1 (MOI)) for 16h or
Sendai virus (40 HAU/ml) for 16h.
Generation of Triad3A knock-down cells
shRNA1 Triad3A and shRNA Control were transfected into
A549 cells by using the Fugene 6 transfection reagent (Roche
Applied Sciences). Cells were selected beginning at 48h post-
transfection for 3 weeks in Dulbecco’s modified Eagle’s medium
containing 10% heat-inactivated calf serum, glutamine, antibiot-
ics, and 2 mg/ml G418 (Invitrogen); individual clones were
screened for maximal knockdown of Triad3A by immunoblot.
In vivo ubiquitination assay
293T cells were transiently transfected with 2.5 mg Flag-
TRAF3, 250 ng myc-Triad3A, 250 ng myc-Triad3A S320D and
1 mg HA-Ubiquitin expression plasmids. At 6h post-transfection,
cells were treated with 10 mM of Mg132 where indicated. Samples
were harvested 24h post-transfection, lysed using a 1% NP-40 lysis
buffer (50 mM Tris-HCL ph 7.5, 150 mM NaCl, 5mM EDTA,
50 mM NaF, 1% NP-40, 10% glycerol, 30 mMb-glycerophos-
phate, 1mM orthovanadate (Na3VO4), 1 mM phenyl-methyl-
sulfonyl fluoride (PMSF)) supplemented with 0.1% protease
inhibitor cocktail (Sigma-Aldrich, Oakville, Ont.) and the
deubiquitinase inhibitor N-ethylmaleimide (NEM, 10 mM, Sig-
ma-Aldrich, Oakville, Ont). Samples were boiled for 10 minutes in
1% SDS and diluted 10 times in lysis buffer. 250 mg of proteins
were then immunoprecipitated overnight at 4uC with constant
agitation with 0.5 mg of anti-Flag (M2; Sigma-Aldrich) crosslinked
to 30 ml of protein A/G PLUS-Agarose (Santa Cruz Biotechnol-
ogy). Immunoprecipitated protein was washed 4 times with
supplemented lysis buffer, denatured in 2% SDS-loading dye,
and loaded onto a 7.5% acrylamide gel for SDS-PAGE analysis
followed by transfer to nitrocellulose membrane. Polyubiquitina-
tion was detected by immunoblotting with a monoclonal anti-HA
antibody (Sigma-Aldrich, Oakville, Canada). A549 cells were
infected with Sendai virus (40 HAU/ml) in the presence of 5 mM
of lactacystin and samples were collected every 4h p.i. Samples
were lysed as previously described and samples were boiled for
10 minutes in 1% SDS and diluted 10 times in lysis buffer. 500 mg
of proteins were then immunoprecipitated overnight at 4uC with
constant agitation with 0.5 mg of anti-TRAF3 (sc-6933 Santa
Cruz, USA) crosslinked to 30 ml of protein A/G PLUS-Agarose
(Santa Cruz Biotechnology). Immunoprecipitated protein was
washed 4 times with supplemented lysis buffer, denatured in 2%
SDS-loading dye, and loaded onto a 7.5% acrylamide gel for SDS-
PAGE analysis followed by transfer to nitrocellulose membrane.
Polyubiquitination was detected by immunoblotting with poly-
clonal Lys
48 and Lys
63 anti-ubiquitin specific antibodies (Millipore,
USA).
Co-immunoprecipitation
Cells were lysed in lysis buffer (50 mM Tris-HCl, pH 7.5,
250 mM NaCl, 0.5% NP-40) supplemented with 0.1% protease
inhibitor cocktail (Sigma-Aldrich, Oakville, Canada). 250 mgo f
proteins were then immunoprecipitated overnight at 4uC with
constant agitation with either 0.5 mg of anti-myc (9E10; Sigma-
Aldrich) or 0.5 mg of anti-Flag (M2; Sigma-Aldrich) or 0.5 ug of
anti-TRAF3 crosslinked to 30 ml of protein A/G PLUS-Agarose
(Santa Cruz Biotechnology). After extensive washing with lysis
buffer, the immunocomplexes were analyzed by immunoblotting
as described.
Immunoblot analysis
Whole cell extracts (20–40 mg) were separated in 7.5–12%
acrylamide gel by SDS-PAGE and were transferred to a
nitrocellulose membrane (BioRad, Mississauga, Canada) at 4uC
for 1h at 100 V in a buffer containing 30 mM Tris, 200 mM
glycine and 20% (vol/vol) methanol. Membranes were blocked for
1h at room temperature in 5% (vol/vol) dried milk in PBS and
0.1% (vol/vol) Tween-20 and then were probed with primary
antibodies. Anti-Flag (M2), anti-Hemagglutinin HA (H7), or anti-
myc (9E10) each at a concentration of 1 mg/ml were purchased
from Sigma-Aldrich (Sigma-Aldrich, Oakville, Canada); anti-
MAVS (1:1000, in-house previously described [14]) were prepared
in blocking solution plus 0.02% sodium azide. Anti-IRF-3 (1:5000,
IBL, Japan), anti-b-Actin (1:5000, MAB1501 Millipore, USA),
anti-Triad3A (1:1000, ProSci Inc. USA), anti-RIG-I (1:1000,
rabbit polyclonal Ab, previously described [14]), anti-VSV
(1:3000, rabbit polyclonal Ab raised against VSV proteins G, N,
and M), anti-ISG56 (1:1000, gift from Dr. Ganes Sen, Cleveland
Clinic), anti-TRAF3 (1 mg/ml, sc-6933 Santa Cruz, Cal, USA),
anti-IRF-3 Ser 396 (1:1000, rabbit anti-peptide Ab, previously
described [54]), and Lys
48 and Lys
63 anti-ubiquitin specific
antibody (1:1000, Millipore, USA) were prepared in 3% BSA/
PBS/0.03% sodium azide.
IRF-3 dimerization
Whole cell extracts were prepared in Nonidet P-40 lysis buffer
(50 mM Tris, pH 7.4, 150 mM NaCl, 30 mM NaF, 5 mM
EDTA, 10% glycerol, 1.0 mM Na3VO4,4 0m Mb-glycerophos-
phate, 0.1 mM phenylmethylsulfonyl fluoride, 5 mg/ml of each
leupeptin, pepstatin, and aprotinin, and 1% Nonidet P-40), and
then were subjected to electrophoresis on 7.5% native acrylamide
gels, which were pre-run for 30 min at 4uC. The electrophoresis
buffers were composed of an upper chamber buffer (25 mM Tris,
pH 8.4, 192 mM glycine, and 1% sodium deoxycholate) and a
lower chamber buffer (25 mM Tris, pH 8.4, 192 mM glycine).
Gels were soaked in SDS running buffer (25 mM Tris, pH 8.4,
250 mM glycine, 0.1% SDS) for 30 min at 25uC and were then
electrophoretically transferred on Hybond-C nitrocellulose mem-
branes (Amersham Biosciences) in 25 mM Tris, pH 8.4, 192 mM
glycine, and 20% methanol for 1 h at 4uC. Membranes were
blocked in phosphate-buffered saline containing 5% (vol/vol)
nonfat dry milk and 0.05% (vol/vol) Tween 20 for 1 h at 25uC
and then were blotted with an antibody against IRF-3 (1 mg/ml) in
blocking solution for 1 h at 25uC. After washing the membranes
five times in phosphate-buffered saline/0.05% Tween, they were
incubated for 1 h with horseradish peroxidase-conjugated goat
anti-rabbit IgG (1:4000) in blocking solution. Immunoreactive
bands were visualized by enhanced chemiluminescence (Amer-
sham Biosciences).
Real-time PCR
Quantitative PCR assays were performed in triplicate using the AB
7500 Real-time PCR System (Applied Biosystems). The primers used
were as follows: IFN-ß,5 9-TTGTGCTTCTCCACTACAGC-39
(forward) and 59-CTGTAAGTCTGTTAATGAAG-39 (reverse);
IFN-a2,5 9-CCTGATGAAGGAGGACTCCATT-39 (forward)
and 59-AAAAAGGTGAGCTGGCATACG-39 (reverse); ISG15,
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CAGCCAGAACAGGT-39 (reverse); ISG56 59-CAACCAAG-
CAAATGTGAGGA-39 (forward) and 59-AGGGGAAGCAAA-
GAAAATGG-39 (reverse); CXCL10 59-TTCCTGCAAGCCAAT-
TTTGTC-39 (forward) and 59-TCTTCTCACCCTTCTTTTT-
CATTGT-39 (reverse); STAT1 59-CCTGCTGCGGTTCAGTGA-
39 (forward) and 59-TCCACCCATGTGAATGTGATG-39 (reverse);
ß-Actin,5 9-CCTTCCTGGGCATGGAGTCCT-39 (forward) and 59-
AATCTCATCTTGTTTTCTGCG-39 (reverse). All data are pre-
sented as a relative quantification with efficiency correction based on
the relative expression of target genes versus ß-Actin as reference gene.
Standard curves and PCR efficiencies were obtained using serial
dilutions of pooled cDNA prepared from stable shRNA1 Triad3A and
shRNA control A549 cells infected with Sendai virus (40 HAU/ml) for
12h. Data were then collected using the AB 7500 Real-time PCR
System (Applied Biosystems) and analyzed by comparative CT method
using the SDS version 1.3.1 Relative Quantification software.
ELISA
The supernatants from stable shRNA Triad3A and shRNA
Control cells infected with Sendai virus (40 HAU/ml) were
collected at 12h p.i. The concentrations of IFN-b and IFN-a in the
supernatants were measured using ELISA kits (PBL Biomedical
Laboratories, Piscataway, NJ).
Supporting Information
Figure S1 Triad3A blocks RIG-I/MAVS and TRIF-mediated
ISRE transactivation. 293T cells were transfected with pRLTK
control plasmid (100 ng), ISRE-Luc reporter plasmid (200 ng),
RIG-I (A)-, MAVS (B)-, TRIF (C)-, or TBK1(D)-expressing
plasmid (200 ng) together with an increase amount of Triad3A
expression plasmid (0, 50, 200, and 1000 ng) as indicated. In all
transfections, the pcDNA3 vector was added to bring the total
plasmids to 1500 ng. Luciferase activity was analyzed at 24h post-
transfection by the Dual-Luciferase Reporter assay as described by
the manufacturer (Promega). Relative luciferase activity was
measured as fold activation (relative to the basal level of reporter
gene in the presence of pcDNA3 vector after normalization with
co-transfected RLU activity); values are mean 6 S.D. for three
experiments.
Found at: doi:10.1371/journal.ppat.1000650.s001 (0.37 MB TIF)
Figure S2 Triad3A inhibits MDA5 and CD4-TLR3 transacti-
vation. 293T cells were transfected with pRLTK control plasmid
and IFNB-pGL3 (A), NF-kB (B) reporter plasmid and the pcDNA3
vector or expression plasmids encoding MDA5 and CD4-TLR3,
as well as Triad3A expression plasmid as indicated. Luciferase
activity was analyzed at 24h post-transfection by the Dual-
Luciferase Reporter assay as described by the manufacturer
(Promega). Relative luciferase activity was measured as fold
activation (relative to the basal level of reporter gene in the
presence of pcDNA3 vector after normalization with co-transfect-
ed RLU activity); values are mean 6 S.D. for three experiments.
Found at: doi:10.1371/journal.ppat.1000650.s002 (0.44 MB TIF)
Figure S3 dsRNA treatment promotes TRAF3 degradation.
A549 cells were treated with dsRNA 20mg/ml and cells were
collected every 2h post-treatment. Cell lysates were analyzed by
immunoblotting with anti-TRAF3, anti-SeV, and anti-ISG56
antibodies.
Found at: doi:10.1371/journal.ppat.1000650.s003 (0.25 MB TIF)
Figure S4 Triad3A S320D does not alter TRAF3 protein
expression. 293T cells were co-transfected with expression vectors
for Flag-tagged TRAF3 and increasing amount of expression
vector for myc-tagged Triad3A S320D as indicated. The cells were
subsequently lysed, and cell lysates were resolved by SDS-PAGE.
The expression levels of TRAF3, Triad3A S320D, and b-actin
were analyzed by immunoblotting with antibodies against myc,
Flag, or b-Actin, respectively.
Found at: doi:10.1371/journal.ppat.1000650.s004 (0.39 MB TIF)
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